Clinical Trials List
2025-11-01 - 2030-06-07
Others
Not yet recruiting5
Recruiting2
ICD-10L40.0
Psoriasis vulgaris
ICD-10L40.1
Generalized pustular psoriasis
ICD-10L40.2
Acrodermatitis continua
ICD-10L40.3
Pustulosis palmaris et plantaris
ICD-10L40.4
Guttate psoriasis
ICD-10L40.8
Other psoriasis
ICD-10L40.9
Psoriasis, unspecified
ICD-9696.1
Other psoriasis
A phase 3b/4, multicenter, randomized, open-label, long-term safety trial comparing deucravacitinib with ustekinumab in participants with moderate to severe plaque psoriasis (PRAGMATYK).
-
Trial Applicant
BRISTOL-MYERS SQUIBB (TAIWAN) LTD.
-
Sponsor
Bristol-Myers Squibb Taiwan Co., Ltd.
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/06
Investigators and Locations
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- Chih-Chieh Chan 無
- 陳柏樺 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
- DINGDAR LEE 無
- 吳貞宜 無
- Cheng-Yuan Li 無
- Chih-Chiang Chen 無
- 何翊芯 無
- 馬聖翔 無
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Not yet recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
2. At the screening follow-up visit, participants must have at least one of the following cardiovascular risk factors:
- Currently a smoker.
Note: E-cigarettes are not considered smoking.
- Diagnosed with hypertension (defined as blood pressure ≥ 130/90 mm Hg) or using antihypertensive medication.
- Diagnosed with dyslipidemia (defined as total cholesterol ≥ 240 mg/dL, or LDL cholesterol ≥ 160 mg/dL, or HDL cholesterol < 40 mg/dL for men (as determined at birth) and < 50 mg/dL for women (as determined at birth), or using lipid-lowering medication [such as statins]).
- Type 1 or 2 diabetes.
- History of one or more of the following cardiovascular events: coronary revascularization (including percutaneous coronary intervention [PCI] or coronary artery bypass grafting [CABG]), myocardial infarction, cardiac arrest, hospitalization for unstable angina, acute coronary syndrome, stroke, or transient ischemic attack. - Obesity, defined as a body mass index ≥ 30 kg/m2.
- Family history of premature coronary heart disease (defined as: a first-degree male relative (sex at birth) under 55 years of age, or a first-degree female relative (sex at birth) under 65 years of age, who has had clinical coronary artery disease or sudden death.
3. You must be at least 40 years old.
Exclusion Criteria
- Recent occurrence of one of the following cardiovascular events: myocardial infarction, stroke, coronary revascularization, or venous thromboembolism within 90 days prior to Day 1.
- Unstable cardiovascular disease, defined as: a recent clinical cardiovascular event (e.g., unstable angina, rapid atrial fibrillation) or hospitalization for heart problems (e.g., implantation of a pacemaker, heart failure) within 90 days prior to Day 1.
- Evidence of active cancer, or a history of cancer (solid organ or hematologic malignancy, including myelodysplastic syndrome) or lymphoproliferative disorder (excluding resected basal cell carcinoma or squamous cell carcinoma of the skin, or treated cervical carcinoma in situ without evidence of recurrence) within the past 5 years.
The Estimated Number of Participants
-
Taiwan
100 participants
-
Global
3040 participants
